Izana Bioscience has initiated a two-center compassionate use study of its drug namilumab for treatment of patients with rapidly worsening COVID-19.

Namilumab is a human monoclonal antibody therapy that targets granulocyte-macrophage colony stimulating factor. It is currently in late-stage clinical development for the treatment of rheumatoid arthritis and ankylosing spondylitis.